Roadmap To Affinity-tuned Antibodies For Enhanced Chimeric Antigen Receptor T Cell Function And Selectivity
Connect with us

Plato Vertical Search

Big Data

Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity

Chimeric antigen receptor (CAR) T cells have revolutionized cancer treatment. CARs use antibody-derived binding domains to redirect T cells to antigens expressed on the surface of cancer cells. However, the high affinity of most currently used CAR-binding domains results in excessive T-cell activation limiting CAR T-cell persistence and the inability to differentiate between antigen-high tumor cells and antigen-low healthy cells. We review recent data on the use of low-affinity CAR-binding domains and evaluate technologies and approaches to engineer and screen low-affinity antibody variants for CAR T-cell development.

    • Sadelain M.

    CD19 CAR T cells.

    Cell. 2017; 171: 1471

    • Raje N.
    • et al.

    Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.

    N. Engl. J. Med. 2019; 380: 1726-1737

    • Mullard A.

    FDA approves 100th monoclonal antibody product.

    Nat. Rev. Drug Discov. 2021; 20: 491-495

    • Ghorashian S.
    • et al.

    Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.

    Nat. Med. 2019; 25: 1408-1414

    • Caserta S.
    • et al.

    Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-associated antigens.

    J. Immunol. 2010; 185: 6545-6554

    • Xu X.
    • et al.

    Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies.

    Front. Immunol. 2019; 10: 2664-2674

    • Shah N.N.
    • Fry T.J.

    Mechanisms of resistance to CAR T cell therapy.

    Nat. Rev. Clin. Oncol. 2019; 16: 372-385

    • Watanabe K.
    • et al.

    Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology.

    Front. Immunol. 2018; 9: 2486

    • Cheever M.A.
    • et al.

    The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research.

    Clin. Cancer Res. 2009; 15: 5323-5337

    • Sun S.
    • et al.

    Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies.

    J Immunol Res. 2018; 2018: 2386187

    • Hirayama A.V.
    • Turtle C.J.

    Toxicities of CD19 CAR-T cell immunotherapy.

    Am. J. Hematol. 2019; 94: S42-S49

    • Mamonkin M.
    • et al.

    A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.

    Blood. 2015; 126: 983-992

    • Liu X.
    • et al.

    Driving better and safer HER2-specific CARs for cancer therapy.

    Oncotarget. 2017; 8: 62730-62741

    • Morgan R.A.
    • et al.

    Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

    Mol. Ther. 2010; 18: 843-851

    • Solouki S.
    • et al.

    TCR signal strength and antigen affinity regulate CD8(+) memory T cells.

    J. Immunol. 2020; 205: 1217-1227

    • Zehn D.
    • et al.

    Complete but curtailed T-cell response to very low-affinity antigen.

    Nature. 2009; 458: 211-214

    • Drent E.
    • et al.

    Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor–engineered T cells.

    Clin. Cancer Res. 2019; 25: 4014

    • Liu X.
    • et al.

    Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice.

    Cancer Res. 2015; 75: 3596

    • Drent E.
    • et al.

    A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization.

    Mol. Ther. 2017; 25: 1946-1958

    • Chmielewski M.
    • et al.

    T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.

    J. Immunol. 2004; 173: 7647

    • Arcangeli S.
    • et al.

    Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia.

    Mol. Ther. 2017; 25: 1933-1945

    • Song D.-G.
    • et al.

    A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.

    Oncotarget. 2015; 6: 21533-21546

    • Caruso H.G.
    • et al.

    Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity.

    Cancer Res. 2015; 75: 3505-3518

    • Richman S.A.
    • et al.

    High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model.

    Cancer Immunol. Res. 2018; 6: 36-46

    • Maus M.V.
    • et al.

    An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.

    Mol. Ther. Oncolytics. 2016; 3: 1-9

    • Roddie C.
    • et al.

    Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

    J. Clin. Oncol. 2021; 39 (JCO2100917): 3352-3363

    • Gogishvili T.
    • et al.

    SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes.

    Blood. 2017; 130: 2838-2847

    • Szöőr Á.
    • et al.

    Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.

    Cancer Lett. 2020; 484: 1-8

    • Chen X.
    • et al.

    Rational tuning of CAR tonic signaling yields superior T-cell therapy for cancer.

    bioRxiv. 2020; (2020.10.01.322990)

    • Caruana I.
    • et al.

    From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

    Semin. Oncol. 2014; 41: 661-666

    • Abbott R.C.
    • et al.

    Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma.

    Clin. Transl. Immunol. 2021; 10e1283

    • Xu J.L.
    • Davis M.M.

    Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities.

    Immunity. 2000; 13: 37-45

    • D’Angelo S.
    • et al.

    Many routes to an antibody heavy-chain CDR3: necessary, yet insufficient, for specific binding.

    Front. Immunol. 2018; 9: 395

    • Simons J.F.
    • et al.

    Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR.

    MAbs. 2020; 12: 1803646

    • Cirino P.C.
    • et al.

    Generating mutant libraries using error-prone PCR.

    in: Arnold F.H. Georgiou G. Directed Evolution Library Creation: Methods and Protocols. Humana Press, 2003: 3-9

    • Wilson D.S.
    • Keefe A.D.

    Random mutagenesis by PCR.

    Curr. Protoc. Mol. Biol. 2001; 51 (Chapter 8, Unit 8.3): 8.3.1-8.3.9

    • Liu B.
    • et al.

    Improving the mutagenesis efficiency of the Kunkel method by codon optimization and annealing temperature adjustment.

    New Biotechnol. 2020; 56: 46-53

    • Maruthachalam B.V.
    • et al.

    A single-framework synthetic antibody library containing a combination of canonical and variable complementarity-determining regions.

    ChemBioChem. 2017; 18: 2247-2259

    • Kunkel T.A.

    Rapid and efficient site-specific mutagenesis without phenotypic selection.

    Proc. Natl. Acad. Sci. U. S. A. 1985; 82: 488-492

    • Tundidor Y.
    • et al.

    Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity.

    Sci. Rep. 2020; 10: 1194

    • Chang A.
    • et al.

    A novel phage display vector for selection of target-specific peptides.

    Protein Eng. Des. Sel. 2020; 33

    • Huang R.
    • et al.

    Improvements to the Kunkel mutagenesis protocol for constructing primary and secondary phage-display libraries.

    Methods. 2012; 58: 10-17

    • Rouet R.
    • et al.

    Generation of human single domain antibody repertoires by Kunkel mutagenesis.

    Methods Mol. Biol. 2012; 907: 195-209

    • Marks J.D.
    • et al.

    By-passing immunization: building high affinity human antibodies by chain shuffling.

    Bio/Technology. 1992; 10: 779-783

    • Wijesuriya S.D.
    • et al.

    Antibody engineering to improve manufacturability.

    Protein Expr. Purif. 2018; 149: 75-83

    • Weiss G.A.
    • et al.

    Rapid mapping of protein functional epitopes by combinatorial alanine scanning.

    Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 8950-8954

    • Marimuthu P.
    • Singaravelu K.

    Prediction of hot spots at myeloid cell leukemia-1–inhibitor interface using energy estimation and alanine scanning mutagenesis.

    Biochemistry. 2018; 57: 1249-1261

    • Robin G.
    • et al.

    Restricted diversity of antigen binding residues of antibodies revealed by computational alanine scanning of 227 antibody–antigen complexes.

    J. Mol. Biol. 2014; 426: 3729-3743

    • Heinemann P.M.
    • et al.

    Active-site loop variations adjust activity and selectivity of the cumene dioxygenase.

    Nat. Commun. 2021; 12: 1095

    • Kim D.
    • et al.

    Molecular characterization of single-chain antibody variable fragments (scFv) specific to Pep27 from Streptococcus pneumoniae.

    Biochem. Biophys. Res. Commun. 2018; 501: 718-723

    • Yamashita T.
    • et al.

    Affinity improvement of a cancer-targeted antibody through alanine-induced adjustment of antigen-antibody interface.

    Structure. 2019; 27: 519-527.e5

    • Zoller M.J.

    New molecular biology methods for protein engineering.

    Curr. Opin. Biotechnol. 1991; 2: 526-531

    • Öling D.
    • et al.

    Large scale synthetic site saturation GPCR libraries reveal novel mutations that alter glucose signaling.

    ACS Synth. Biol. 2018; 7: 2317-2321

    • Lippow S.M.
    • et al.

    Computational design of antibody-affinity improvement beyond in vivo maturation.

    Nat. Biotechnol. 2007; 25: 1171-1176

    • Tue-ngeun P.
    • et al.

    Improved scFv anti-HIV-1 p17 binding affinity guided from the theoretical calculation of pairwise decomposition energies and computational alanine scanning.

    Biomed. Res. Int. 2013; 2013: 713585

    • Warszawski S.
    • et al.

    Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces.

    PLoS Comput. Biol. 2019; 15: e1007207

    • Baran D.
    • et al.

    Principles for computational design of binding antibodies.

    Proc. Natl. Acad. Sci. 2017; 114: 10900

    • Norman R.A.
    • et al.

    Computational approaches to therapeutic antibody design: established methods and emerging trends.

    Brief. Bioinform. 2019; 21: 1549-1567

    • Hoogenboom H.R.

    Selecting and screening recombinant antibody libraries.

    Nat. Biotechnol. 2005; 23: 1105-1116

    • Lad L.
    • et al.

    High-throughput kinetic screening of hybridomas to identify high-affinity antibodies using bio-layer interferometry.

    J. Biomol. Screen. 2015; 20: 498-507

    • Valldorf B.
    • et al.

    Antibody display technologies: selecting the cream of the crop.

    Biol. Chem. 2021;

    • Ljungars A.
    • et al.

    Deep mining of complex antibody phage pools generated by cell panning enables discovery of rare antibodies binding new targets and epitopes.

    Front. Pharmacol. 2019; 10: 847

    • Dyson M.R.
    • et al.

    Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.

    mAbs. 2020; 12: 1829335

    • Boder E.T.
    • et al.

    Engineering antibodies by yeast display.

    Arch. Biochem. Biophys. 2012; 526: 99-106

    • Bazan J.
    • et al.

    Phage display—a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.

    Hum. Vaccin. Immunother. 2012; 8: 1817-1828

    • Zahnd C.
    • et al.

    Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target.

    Nat. Methods. 2007; 4: 269-279

    • Jost C.
    • et al.

    CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins.

    MAbs. 2020; 12: 1840709

    • Ochi T.
    • et al.

    A single-chain antibody generation system yielding CAR-T cells with superior antitumor function.

    Commun. Biol. 2021; 4: 273

    • Beerli R.R.
    • et al.

    Isolation of human monoclonal antibodies by mammalian cell display.

    Proc. Natl. Acad. Sci. 2008; 105: 14336-14341

    • Ho M.
    • Pastan I.

    Mammalian cell display for antibody engineering.

    Methods Mol. Biol. (Clifton, N.J.). 2009; 525: 337-xiv

    • González P.A.
    • et al.

    T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell.

    Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 4824-4829

    • Roddie C.
    • et al.

    AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL.

    Blood. 2019; 134: 226

    • Govern C.C.
    • et al.

    Fast on-rates allow short dwell time ligands to activate T cells.

    Proc. Natl. Acad. Sci. 2010; 107: 8724

    • Hudecek M.
    • et al.

    Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

    Clin. Cancer Res. 2013; 19: 3153

    • Gilchuk P.
    • et al.

    Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics.

    Nat. Biomed. Eng. 2020; 4: 1030-1043

    • Hua X.
    • et al.

    Competitive and noncompetitive phage immunoassays for the determination of benzothiostrobin.

    Anal. Chim. Acta. 2015; 890: 150-156

    • Wang J.
    • et al.

    Screening and identification of RhD antigen mimic epitopes from a phage display random peptide library for the serodiagnosis of haemolytic disease of the foetus and newborn.

    Blood Transfus. 2019; 17: 53-59

    • Yang X.
    • et al.

    Hapten synthesis and the development of an ultrasensitive indirect competitive ELISA for the determination of diethylstilbestrol in food samples.

    Sci. Rep. 2020; 10: 3270

    • Daigo K.
    • et al.

    A simple hybridoma screening method for high-affinity monoclonal antibodies using the signal ratio obtained from time-resolved fluorescence assay.

    Anal. Biochem. 2006; 351: 219-228

    • Peruski A.H.
    • et al.

    Rapid and sensitive detection of biological warfare agents using time-resolved fluorescence assays.

    J. Immunol. Methods. 2002; 263: 35-41

    • Xiong Y.
    • et al.

    Emerging strategies to enhance the sensitivity of competitive ELISA for detection of chemical contaminants in food samples.

    TrAC Trends Anal. Chem. 2020; 126115861

    • Geuijen C.A.
    • et al.

    Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery.

    J. Immunol. Methods. 2005; 302: 68-77

    • Worthington J.E.
    • et al.

    A comparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodies.

    Hum. Immunol. 2001; 62: 1178-1184

    • Daugherty P.S.
    • et al.

    Flow cytometric screening of cell-based libraries.

    J. Immunol. Methods. 2000; 243: 211-227

    • Hemadou A.
    • et al.

    An innovative flow cytometry method to screen human scFv-phages selected by in vivo phage-display in an animal model of atherosclerosis.

    Sci. Rep. 2018; 8: 15016

    • Georgiou G.

    Analysis of large libraries of protein mutants using flow cytometry.

    in: Advances in Protein Chemistry. Academic Press, 2001: 293-315

    • Knowling S.
    • et al.

    Direct comparison of label-free biosensor binding kinetics obtained on the Biacore 8K and the Carterra LSA.

    SLAS Discov. 2020; 25: 977-984

    • Lofgren J.A.
    • et al.

    Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab.

    J. Immunol. 2007; 178: 7467

    • Khan S.H.
    • et al.

    A versatile method to measure the binding to basic proteins by surface plasmon resonance.

    Anal. Biochem. 2012; 421: 385-390

    • Brown M.E.
    • et al.

    Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors.

    PLoS ONE. 2020; 15e0229206

    • Beckmann R.
    • et al.

    DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously.

    Nat. Commun. 2021; 12: 708

    • Hunter S.A.
    • et al.

    An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy.

    Commun. Biol. 2021; 4: 452

    • Bee C.
    • et al.

    Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions.

    PLoS One. 2012; 7: e36261

    • Abdiche Y.
    • et al.

    Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet.

    Anal. Biochem. 2008; 377: 209-217

    • Petersen R.L.

    Strategies using bio-layer interferometry biosensor technology for vaccine research and development.

    Biosensors. 2017; 7: 49

    • Leonard P.
    • et al.

    High throughput ranking of recombinant avian scFv antibody fragments from crude lysates using the Biacore A100.

    J. Immunol. Methods. 2007; 323: 172-179

    • Baeuerle P.A.
    • et al.

    Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.

    Nat. Commun. 2019; 10: 2087

    • Liu Y.
    • et al.

    Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors.

    Sci. Transl. Med. 2021; 13

    • Bloemberg D.
    • et al.

    A high-throughput method for characterizing novel chimeric antigen receptors in Jurkat cells.

    Mol. Ther. Methods Clin. Dev. 2020; 16: 238-254

    • Lever M.
    • et al.

    Phenotypic models of T cell activation.

    Nat. Rev. Immunol. 2014; 14: 619-629

    • Shakiba M.
    • et al.

    The impact of TCR affinity on T cell differentiation and dysfunction in tumors.

    J. Immunol. 2018; 200: 57.24

    • Stone J.D.
    • et al.

    T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity.

    Immunology. 2009; 126: 165-176

    • Moghimi B.
    • et al.

    Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.

    Nat. Commun. 2021; 12: 511

    • Radhakrishnan S.V.
    • et al.

    CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.

    Nat. Commun. 2020; 11: 798

    • Park S.
    • et al.

    Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity.

    Sci. Rep. 2017; 7: 14366

    • Laustsen A.H.
    • et al.

    In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies.

    Nat. Commun. 2018; 9: 3928

  • Biacore Assay Handbook, GE Healthcare Life Sciences.

    • Rich R.L.
    • Myszka D.G.

    Survey of the year 2007 commercial optical biosensor literature.

    J. Mol. Recognit. 2008; 21: 355-400

    • Vokali E.
    • et al.

    Lymphatic endothelial cells prime naïve CD8+ T cells into memory cells under steady-state conditions.

    Nat. Commun. 2020; 11: 538

    • Joshi N.S.
    • Kaech S.M.

    Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation.

    J. Immunol. 2008; 180: 1309

    • Robbins P.F.
    • et al.

    Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.

    J. Immunol. 2008; 180: 6116

    • Zhao Y.
    • et al.

    High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.

    J. Immunol. 2007; 179: 5845

    • Carter P.
    • et al.

    Humanization of an anti-p185HER2 antibody for human cancer therapy.

    Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 4285-4289

    • Schier R.
    • et al.

    Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.

    J. Mol. Biol. 1996; 263: 551-567

    • Heitner T.
    • et al.

    Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library.

    J. Immunol. Methods. 2001; 248: 17-30

    • Jin M.
    • et al.

    Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity.

    Proc. Natl. Acad. Sci. 2006; 103: 5758

    • Figini M.
    • et al.

    Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection.

    Cancer Res. 1998; 58: 991-996

    • Yang J.
    • et al.

    Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.

    PLoS One. 2011; 6e21018

  • Source:

    Related Streams


    Ex-Singapore Parliamentarian Calvin Cheng forms the first regulated non-fungible token (NFT) and fan token investment holding company in Dubai. The Dubai Virtual Asset Regulatory...


    Andrew Baines, 46, father of two and medical cannabis patient in the U.K., faced a terrible fate for also being a cannabis caregiver. Namely...


    Andrew Baines, 46, father of two and medical cannabis patient in the U.K., faced a terrible fate for also being a cannabis caregiver. Namely...


    Andrew Baines, 46, father of two and medical cannabis patient in the U.K., faced a terrible fate for also being a cannabis caregiver. Namely...